Cite
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure
MLA
Flanagan, E., et al. Infliximab, Adalimumab and Vedolizumab Concentrations across Pregnancy and Vedolizumab Concentrations in Infants Following Intrauterine Exposure. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315721132&authtype=sso&custid=ns315887.
APA
Flanagan, E., Gibson, P., Wright, E., Moore, G., Sparrow, M., Connell, W., Kamm, M., Begun, J., Christensen, B., De Cruz, P., Shelton, E., Dowling, D., Andrews, J., Brown, S., Niewiadomski, O., Ward, M., Rosella, O., Rosella, G., Kiburg, K., … Bell, S. (2020). Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
Chicago
Flanagan, E, Pr Gibson, Ek Wright, Gt Moore, Mp Sparrow, W Connell, Ma Kamm, et al. 2020. “Infliximab, Adalimumab and Vedolizumab Concentrations across Pregnancy and Vedolizumab Concentrations in Infants Following Intrauterine Exposure.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315721132&authtype=sso&custid=ns315887.